Table 1 Baseline characteristics of 189 breast cancer patients with brain metastases
From: Clinical implication of Time To Brain Metastasis (TTBM) according to breast cancer subtypes
Characteristics | Total N=189 (%) |
|---|---|
Median age (range) | |
at initial diagnosis of distant metastasis | 46 (25–85) |
at initial diagnosis of BM | 48 (26–87) |
Menopausal status at initial diagnosis | |
premenopausal | 104 (55%) |
postmenopausal | 42 (22%) |
unknown | 43 (23%) |
Histology | |
Invasive ductal carcinoma | 163 (86%) |
Invasive lobular carcinoma | 3 (2%) |
Others | 10 (5%) |
Unknown | 13 (7%) |
Stage at initial diagnosis | |
I/II | 81 (43%) |
III | 76 (40%) |
IV | 18 (10%) |
unknown | 14 (7%) |
Tumor subtype | |
HR-positive/HER2-negative | 45 (23%) |
HER2-positive irrespective of HR status | 86 (47%) |
TNBC | 58 (31%) |
AntiHER2 Treatment among HER2-positive patients (N=86) | |
Before BM diagnosis | 47 (51%) |
as an adjuvant treatment | 12 |
as a neoadjuvant treatment | 1 |
as a palliative treatment | 34 |
After BM diagnosis | 15 (17%) |
No anti-HER2 treatment | 24 (32%) |
Overall Survival, median months | |
from initial distant metastases (mOS) | 23.3 |
from initial BM diagnosis (BM-OS) | 9.6 |